Volition, Werfen Sign Licensing, Commercialization Deal for Antiphospholipid Syndrome Test

Original from: 360dx

Epigenetics firm VolitionRx and Werfen said Tuesday that they have signed a licensing and commercialization deal covering the use of Volition's antiphospholipid syndrome (APS) test with Werfen's analyzers.

Under the agreement, Henderson, Nevada-based Volition will license components of its Nu.Q H3.1 NETs assay to Werfen's Immunoassay Technology Center, and Barcelona, Spain-based Werfen will study the clinical utility of using the test with its analyzers to aid the management of APS patients. Financial and other terms of the agreement were not disclosed.

Volition's Nu.Q NETs test is CE-IVD marked for use in the EU. 

"We are excited to validate further and complete a clinical utility study to determine the potential role of this marker as a risk indicator of thrombosis in APS patients, allowing a better management of this very complex syndrome," Marta Palicio, innovation R&D director for Werfen's Immunoassay Technology Center, said in a statement.

The companies noted that Werfen will have the option to negotiate with Volition on the terms for commercial launch of the test under an exclusive license.

Remi Rabeuf, Volition's VP of corporate alliances and strategic partnerships, added that a diagnosis of APS is typically reached using blood-based panels with two positive results at least 12 weeks apart, and Volition's APS test could provide a low-cost alternative to inform treatment decisions and aid patient monitoring. Patients with the disorder have an increased risk of blood clots with complications such as strokes, heart attacks, pulmonary embolisms, deep vein thrombosis, recurrent miscarriages, and other pregnancy complications.

Source: Volition, Werfen Sign Licensing, Commercialization Deal for Antiphospholipid Syndrome Test